Medication info
Bilda Duo M Tablet 50/1000 Milligrams (Vildagliptin, Metformin Hydrochloride)

Bilda Duo M Tablet 50/1000 Milligrams (Vildagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Vildagliptin›50mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Mothers Pharmaceutical Co., Ltd.
Appearance
Dark yellow elliptical film-coated tablet
Packaging
Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle
Approval status
Active

MFDS item code 202302533 · Approved 2023.08.25 · Insurance code 622805150

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding 100mg of vildagliptin and 2000mg of metformin. Doses of vildagliptin greater than 100mg per day are not recommended. This medicine should generally be taken with food or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients with no prior experience of antidiabetic drug treatment and inadequate glycemic control with monotherapy: The initial dose is 1 tablet of this medicine 50/500mg once daily. The dose may be gradually increased up to 1 tablet of 50/1000mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose is 100mg of vildagliptin per day and the patient's existing dose of metformin. The initial dose of this medicine is determined based on the patient's current treatment regimen. Take 1 tablet of this medicine 50mg/850mg or 50mg/1000mg twice daily, in the morning and evening. 3. Patients switching from combination therapy with vildagliptin and metformin: Patients switching from combination therapy with vildagliptin and metformin to this medicine may start at their existing doses of vildagliptin and metformin. 4. Use in combination with a sulfonylurea or insulin: Administer vildagliptin 50mg twice daily (total daily dose 100mg) and metformin at a dose similar to the existing dose. - When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. No studies have been conducted to evaluate the safety and efficacy of switching from another oral glucose-lowering medicine to this medicine. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. If you forget to take this medicine, take it with your next meal unless it is time to take the missed dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels exceed 2.5 times the upper limit of normal, before starting treatment with this medicine.

Ingredients

Manufacturer
Mothers Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication helps patients with type 2 diabetes to achieve better blood sugar control. When used in conjunction with dietary and exercise therapies, the components vildagliptin and metformin assist in stabilizing blood sugar levels. Therefore, this medication is recommended for those who find it difficult to manage their blood sugar, contributing to healthy blood sugar control with consistent use and lifestyle improvements.

How to take

Adult dose

For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding 100mg of vildagliptin and 2000mg of metformin. Doses of vildagliptin greater than 100mg per day are not recommended. This medicine should generally be taken with food or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients with no prior experience of antidiabetic drug treatment and inadequate glycemic control with monotherapy: The initial dose is 1 tablet of this medicine 50/500mg once daily. The dose may be gradually increased up to 1 tablet of 50/1000mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose is 100mg of vildagliptin per day and the patient's existing dose of metformin. The initial dose of this medicine is determined based on the patient's current treatment regimen. Take 1 tablet of this medicine 50mg/850mg or 50mg/1000mg twice daily, in the morning and evening. 3. Patients switching from combination therapy with vildagliptin and metformin: Patients switching from combination therapy with vildagliptin and metformin to this medicine may start at their existing doses of vildagliptin and metformin. 4. Use in combination with a sulfonylurea or insulin: Administer vildagliptin 50mg twice daily (total daily dose 100mg) and metformin at a dose similar to the existing dose. - When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. No studies have been conducted to evaluate the safety and efficacy of switching from another oral glucose-lowering medicine to this medicine. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. If you forget to take this medicine, take it with your next meal unless it is time to take the missed dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels exceed 2.5 times the upper limit of normal, before starting treatment with this medicine.

Precautions

This medication may cause severe lactic acidosis or hypoglycemia; thus, it should not be used in patients with moderate to severe renal impairment or heart failure. Patients scheduled to undergo tests using radiocontrast iodine should stop taking this medication 48 hours prior to the test and resume only after verifying that renal function is normal post-examination. Patients with allergic reactions to this medication or those with type 1 diabetes or diabetic ketoacidosis should not use it. During severe infections, major trauma, or perioperative periods, this medication should be temporarily discontinued, and resumed only after the condition stabilizes. Patients with poor nutritional status, impaired liver function, or those who consume excessive alcohol should use this medication with caution. It is safer for pregnant or breastfeeding women to avoid this medication. This medication carries a risk of hypoglycemia or lactic acidosis when meals are irregular, during vigorous exercise, or when used in conjunction with other medications, thus caution is required. Occasional side effects such as headaches, dizziness, nausea, and hypoglycemia may occur, so consultation with a doctor is advised if symptoms are severe. Elderly patients with diminished renal function should regularly monitor renal function and adjust the dosage accordingly. It is advisable to avoid alcohol consumption during this medication, and regular blood tests may be necessary as vitamin B12 levels can decrease. Dizziness may occur when driving or operating machinery, so caution is advised. In case of overdose, it is necessary to visit a medical facility immediately for appropriate treatment, and dialysis may be required in some cases. Children should not use this medication as its safety and efficacy have not been established. This medication does not replace insulin treatment for patients requiring insulin, and regular monitoring of blood sugar and glycated hemoglobin is crucial in diabetes management. If symptoms such as blisters or ulcers appear on the skin, immediate reporting to a physician is necessary. Any changes in health status during this medication should be promptly discussed with healthcare providers for appropriate actions.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • hepatitis
  • abnormal liver function
  • elevated transaminase levels
  • angioedema
  • tremors
  • headache
  • dizziness
  • fatigue
Show 36 more
  • nausea
  • hypoglycemia
  • gastroesophageal reflux
  • diarrhea
  • bloating
  • chills
  • blood sugar reduction
  • asthenia
  • sweating
  • constipation
  • arthralgia
  • upper respiratory tract infection
  • nasopharyngitis
  • peripheral edema
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • appetite loss
  • taste disorder
  • erythema
  • pruritus
  • urticaria
  • pancreatitis
  • urticaria
  • blistering
  • exfoliative dermatosis
  • severe and disabling arthralgia
  • cutaneous vasculitis
  • cholecystitis
  • dyspepsia
  • abdominal discomfort
  • gastrointestinal disturbances
  • increased serum amylase
  • increased lipase
  • vesicular pemphigoid

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture; thus, it must be stored in a tightly sealed container. Additionally, it should be kept in a cool place below 30 degrees Celsius to preserve its effectiveness.

Appearance and packaging

Appearance

Dark yellow elliptical film-coated tablet

Package unit

Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.